🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to scientists.

An International Challenge

Gonorrhoea infections are increasing worldwide, with estimates suggesting in excess of 82 million new cases annually. Particularly high rates are reported in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the face of growing infection rates, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for treating gonorrhoea. This disease can lead to major issues, including infertility. Scientists anticipate that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Data and Global Access

As per results published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This places it at an comparable level with the existing first-line therapy, which involves an injection and a pill. The research included over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Doctors directly involved have voiced optimism. Access to a easy-to-administer therapy like this is hailed as a "game-changer" for managing the epidemic. This is considered essential to lessen the impact of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.